The DOI matches its Crossref record; 189 of the 189 references it cites were found in a registry or an index.
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Open accessAbstract
Summary: Investigators developed chimeric antigen receptors (CAR s) for expression on T cells more than 25 years ago. When the CAR is derived from an antibody, the resultant cell should combine the desirable targeting features of an antibody (e.g. lack of requirement for major histocompatibility complex recognition, ability to recognize non‐protein antigens) with the persistence, trafficking, and effector functions of a T cell. This article describes how the past two decades have seen a crescendo of research which has now begun to translate these potential benefits into effective treatments for patients with cancer. We describe the basic design of CAR s, describe how antigenic targets are selected, and the initial clinical experience with CAR‐T cells. Our review then describes our own and other investigators' work aimed at improving the function of CAR s and reviews the clinical studies in hematological and solid malignancies that are beginning to exploit these approaches. Finally, we show the value of adding additional engineering features to CAR‐T cells, irrespective of their target, to render them better suited to function in the tumor environment, and discuss how the safety of these heavily modified cells may be maintained.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Cited by
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,230
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Self-citationPrecision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.011 · Cited by 1,000
Emerging trends and new developments in regenerative medicine: a scientometric update (2000 – 2014)
Chen, C., Dubin, R., & Kim, M. C. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.920813 · Cited by 837
Ali, S. A., Shi, V., Maric, I., Wang, M., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler-Stevenson, M., Feldman, S. A., Hansen, B. G., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711903 · Cited by 757
Immunotherapy for glioma: Current management and future application
Xu, S., Tang, L., Li, X., Fan, F., & Liu, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.002 · Cited by 746
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
Roybal, K. T., Williams, J. Z., Morsut, L., Rupp, L. J., Kolinko, I., Choe, J. H., Walker, W. J., McNally, K. A., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.09.011 · Cited by 721
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
Billingsley, M. M., Singh, N., Ravikumar, P., Zhang, R., June, C. H., & Mitchell, M. J. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04246 · Cited by 636
Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613
Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Shi, V., Bot, A., Rossi, J., Xue, A., Goff, S. L., Yang, J. C., Sherry, R. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3024 · Cited by 569
Heczey, A., Louis, C. U., Savoldo, B., Dakhova, O., Durett, A., Grilley, B., Liu, H., Wu, M. F., Mei, Z., Gee, A., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.012 · Cited by 535
Self-citationKilling Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Benmebarek, M.-R., Karches, C. H., Cadilha, B. L., Lesch, S., Endres, S., & Kobold, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061283 · Cited by 531
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Hu, B., Ren, J., Luo, Y., Keith, B., Young, R. M., Scholler, J., Zhao, Y., & June, C. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.002 · Cited by 506
Du, H., Hirabayashi, K., Ahn, S., Kren, N. P., Montgomery, S. A., Wang, X., Tiruthani, K., Mirlekar, B., Michaud, D., Greene, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.002 · Cited by 479
Self-citationClassification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner, J., Wickman, E., DeRenzo, C., & Gottschalk, S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.015 · Cited by 380
Self-citationChimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Gong, Y., Klein Wolterink, R. G. J., Wang, J., Bos, G. M. J., & Germeraad, W. T. V. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01083-5 · Cited by 379
Ramos, C. A., Ballard, B., Zhang, H., Dakhova, O., Gee, A. P., Mei, Z., Bilgi, M., Wu, M.-F., Liu, H., Grilley, B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94306 · Cited by 375
Self-citationCAR-T design: Elements and their synergistic function
Jayaraman, J., Mellody, M. P., Hou, A. J., Desai, R. P., Fung, A. W., Pham, A. H. T., Chen, Y. Y., & Zhao, W. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102931 · Cited by 374
Alabanza, L., Pegues, M., Geldres, C., Shi, V., Wiltzius, J. J. W., Sievers, S. A., Yang, S., & Kochenderfer, J. N. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.013 · Cited by 351
Xu, X., Sun, Q., Liang, X., Chen, Z., Zhang, X., Zhou, X., Li, M., Tu, H., Liu, Y., Tu, S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02664 · Cited by 347
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 323
Krenciute, G., Prinzing, B. L., Yi, Z., Wu, M.-F., Liu, H., Dotti, G., Balyasnikova, I. V., & Gottschalk, S. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0376 · Cited by 319
Self-citationHeczey, A., Liu, D., Tian, G., Courtney, A. N., Wei, J., Marinova, E., Gao, X., Guo, L., Yvon, E., Hicks, J., et al. (2014) · Blood · doi:10.1182/blood-2013-11-541235 · Cited by 318
Self-citationXie, Y. J., Dougan, M., Jailkhani, N., Ingram, J., Fang, T., Kummer, L., Momin, N., Pishesha, N., Rickelt, S., Hynes, R. O., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817147116 · Cited by 296
Mohammed, S., Sukumaran, S., Bajgain, P., Watanabe, N., Heslop, H. E., Rooney, C. M., Brenner, M. K., Fisher, W. E., Leen, A. M., & Vera, J. F. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.016 · Cited by 281
Self-citationMaking Better Chimeric Antigen Receptors for Adoptive T-cell Therapy
Maus, M. V., & June, C. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1433 · Cited by 265
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Mehta, R. S., & Rezvani, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00283 · Cited by 259
Moon, E. K., Wang, L.-C. S., Bekdache, K., Lynn, R. C., Lo, A., Thorne, S. H., & Albelda, S. M. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1395997 · Cited by 174
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Yilmaz, A., Cui, H., Caligiuri, M. A., & Yu, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00998-9 · Cited by 171
Adolescent and young adult patients with cancer: a milieu of unique features
Sender, L., & Zabokrtsky, K. B. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.92 · Cited by 130
Adoptive T-cell therapy for cancer: the era of engineered T cells
Bonini, C., & Mondino, A. (2015) · European Journal of Immunology · doi:10.1002/eji.201545552 · Cited by 93
Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells
Kumaresan, P. R., da Silva, T. A., & Kontoyiannis, D. P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01939 · Cited by 85
“Finally, a varied range of tumor antigens can be targeted using this system, including glycoproteins and lipids (138, 139).”
BackgroundEngineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials
Esensten, J. H., Bluestone, J. A., & Lim, W. A. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100304 · Cited by 62
Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy
Smith, J. B., Lanitis, E., Dangaj, D., Buza, E., Poussin, M., Stashwick, C., Scholler, N., & Powell, D. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.149 · Cited by 58
Gene therapy with regulatory T cells: A beneficial alliance
Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41
New chimeric antigen receptor design for solid tumors
Wang, Y., Luo, F., Yang, J., Zhao, C., & Chu, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01934 · Cited by 32
Immunomodulation as a Therapy for Aspergillus Infection: Current Status and Future Perspectives
Lauruschkat, C. D., Einsele, H., & Loeffler, J. (2018) · Journal of Fungi · doi:10.3390/jof4040137 · Cited by 32
Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s
DeRenzo, C., & Gottschalk, S. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43032-0_10 · Cited by 12
Self-citation
Metadata
- Authors
- Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2013-12-13
- Volume
- 257
- Issue
- 1
- Pages
- 107-126
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W1977949161
- Cited by
- 508
- References
- 189
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.